{
  "retracted": false,
  "timestamp": 1539734400000,
  "updates": [
    {
      "timestamp": 1571271023756,
      "identifier": {
        "doi": "10.1007/s40264-018-0745-0"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s40264-018-0642-6"
  },
  "journal": "Drug Safety",
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience"
}
